After President-elect Donald Trump chose Robert Kennedy Jr., a longtime vaccine skeptic with no medical or public health training, was chosen to be the next health secretary, Eli Lilly (LLY) chair and CEO David Ricks said his company would fight to defend preserving the Food and Drug Administration as it stands today, Aimee Ortiz of The New York Times reports. Ricks said, “We’re the only country on Earth that does primary data review… I think that’s a value to society we need to keep. We’ll argue that strongly with our new regulator.”
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LLY:
- Viking’s VK2735 likely ‘even better’ than Lilly’s Zepbound, says BTIG
- Eli Lilly’s (LLY) Zepbound Outperformed Novo Nordisk’s Wegovy in Study
- Salesforce up after Q3, GM outlines $5B in China business charges: Morning Buzz
- Morning Movers: Salesforce jumps after Q3, Foot Locker sinks after guidance cut
- Eli Lilly announces topline results from SURMOUNT-5 trial
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
